ArticleOxidative medicine and cellular longevity2023
Exosomes from Adipose-Derived Stem Cells Alleviate Dexamethasone-Induced Bone Loss by Regulating the Nrf2/HO-1 Axis.
Article in Oxidative medicine and cellular longevity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Unlocking the potential of stem cell-derived extracellular vesicles in osteoporosis therapy: a systematic review and meta-analysis of preclinical studies.Journal of translational medicine · 2025Pooled it
- Stem Cell-Derived Extracellular Vesicles for the Treatment of Osteoporosis: A Systematic Review of Preclinical Evidence.Biomedicines · 2026Review
- Adipose-derived stem cell exosomes mitigate ferroptosis and enhance osteogenesis via miR-215-5p-mediated ubiquitin-specific protease 1 suppression.Endocrine journal · 2026Article
- Stem Cells and their Key Derivatives in Degenerative Musculoskeletal Diseases.Stem cell reviews and reports · 2026Review
- Dimethyl fumarate as an immunomodulatory enhancer of adipose-derived mesenchymal stem cells: therapeutic implications.Cell and tissue banking · 2026Article
- Non-Bone-Derived Extracellular Vesicles in Osteoporosis: Evidence Mapping and Nanomedicine Translation.International journal of nanomedicine · 2026Review
- Harnessing Natural Extracellular Vesicles to Combat Age-Related Diseases: From Aging Drivers to Therapeutic Opportunities.International journal of nanomedicine · 2026Review
- Immunoregulatory orchestrations in osteoarthritis and mesenchymal stromal cells for therapy.Journal of orthopaedic translation · 2025Review
- Extracellular vesicles from adipose-derived stem cells in bone regeneration: Mechanisms and therapeutic advances.World journal of stem cells · 2025Review
- Advances in mesenchymal stem cell and exosome-based therapies for aging and age-related diseases.Stem cell research & therapy · 2025Review
- Picroside II regulates the YY1/TGFβ1 axis by inhibiting osteoblast ferroptosis to alleviate symptoms of postmenopausal osteoporosis.Cytotechnology · 2025Article
- The existing evidence for the use of extracellular vesicles in the treatment of osteoporosis: a review.International journal of surgery (London, England) · 2025Review
- Extracellular Vesicles Derived from Adipose-Derived Mesenchymal Stem Cells Alleviate Apoptosis and Oxidative Stress of Retinal Pigment Epithelial Cells Through Activation of Nrf2 Signaling Pathway.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2024Article
- Therapeutic Effect of Liquiritin Carbomer Gel on Topical Glucocorticoid-Induced Skin Inflammation in Mice.Pharmaceutics · 2024Article
- Clinical Applications of Adipose-Derived Stem Cell (ADSC) Exosomes in Tissue Regeneration.International journal of molecular sciences · 2024Review
- Nrf2 activation: a key mechanism in stem cell exosomes-mediated therapies.Cellular & molecular biology letters · 2024Review
- Enhancing osteoporosis treatment with engineered mesenchymal stem cell-derived extracellular vesicles: mechanisms and advances.Cell death & disease · 2024Review
- Non-bone-derived exosomes: a new perspective on regulators of bone homeostasis.Cell communication and signaling : CCS · 2024Review
- Regulation of the Nrf2/HO-1 axis by mesenchymal stem cells-derived extracellular vesicles: implications for disease treatment.Frontiers in cell and developmental biology · 2024Review
- Therapeutic potential of mesenchymal stem cell-derived exosomes in skeletal diseases.Frontiers in molecular biosciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread use of therapeutic glucocorticoids has increased the incidences of glucocorticoid-induced osteoporosis (GIOP). Oxidative stress and mitochondrial dysfunction are major causes of GIOP; therefore, alleviation of excess oxidative stress in osteoblasts is a potential therapeutic strategy for osteoporosis. Exosomes derived from ADSCs (ADSCs-Exos), as novel cell-free therapeutics, can modulate various biological processes, such as immunomodulation, reduce oxidative damage, and promote tissue repair as well as regeneration. In this study, ADSCs-Exos restored the viability and osteogenic potential of MC3T3-E1 cells by attenuating apoptosis, oxidative damage, intracellular ROS generation, and mitochondrial dysfunction. Moreover, after pretreatment with ADSCs-Exos, Nrf2 expressions were upregulated in Dex-stimulated osteoblasts. Inhibitory assays showed that silencing Nrf2 partially eliminated the protective effects of ADSCs-Exos. The rat model assays confirmed that ADSCs-Exos alleviated the Dex-induced increase in oxidation levels, restored bone mass of the distal femur, and increased the expressions of Nrf2 and osteogenic markers in bone tissues. Thus, ADSCs-Exos alleviated apoptosis and oxidative stress by regulating Nrf2/HO-1 expressions after Dex and prevented the development of GIOP in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.